课题基金 / 基金详情

Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer

Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer
双极雄激素治疗进行性去势抵抗性前列腺癌
批准号:
8669473
负责人:
Samuel R Denmeade
金额:
$26.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-15 至 2019-04-30
关键词:
AcetatesActivities of Daily LivingAdrenal GlandsAgonistAndrogen AnaloguesAndrogen AntagonistsAndrogen ReceptorAndrogen TherapyAndrogensAntibodiesBiological AssayBiological MarkersBloodCYP17A1 geneCancer PatientCastrationCell CycleCellsCessation of lifeChronicClinicalClinical DataClinical ResearchClinical TrialsCustomDNADataDevelopmentDoseDown-RegulationEffectivenessEnvironmentEvaluationExonsExposure toGene AmplificationGene RearrangementGenesGenetic TranscriptionGoalsGrowthHeterogeneityHomeostasisHumanIn VitroIndividualInjection of therapeutic agentLengthLicensingLicensing FactorLigandsMalignant neoplasm of prostateMediatingMessenger RNAMetabolic syndromeMetastatic Prostate CancerMonitorMorbidity - disease rateMutationNeoplasm Circulating CellsNeoplasm MetastasisPC3 cell linePatientsPhase II Clinical TrialsPilot ProjectsPlasmaPlayPropertyQuality of lifeRandomizedReceptor GeneReceptor SignalingRecurrenceRegulationResearchResearch Project GrantsResistanceReverse Transcriptase Polymerase Chain ReactionRoleSafetySamplingSerumSex FunctioningSiteSomatic MutationStressSurveysTestingTestosteroneTherapeuticTimeTranscriptVariantabirateronebaseburden of illnesscastration resistant prostate cancerclinical materialcohortdeprivationdigitalexome sequencingfallshormone therapyimprovedin vivoinhibitor/antagonistmenmetabolic abnormality assessmentolder menoverexpressionpalliativepre-clinicalpreclinical studyprostate cancer cellpublic health relevanceresearch clinical testingresponsesafety testingtherapy developmenttreatment strategytumor

项目摘要

项目成果

Samuel R Denmeade的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本研究项目的重点是通过“双极雄激素疗法”(BAT)的管理对去势抵抗性前列腺癌(CRPC)男性的新治疗策略进行临床评估,该治疗策略包括每月注射足够的睾酮,以诱导血清睾酮在一个治疗周期内从生理上的水平快速上升和下降到接近去势的水平。在目前复发性CRPC的治疗模式中,男性越来越多地使用雄激素剥夺疗法(ADT)进行治疗。慢性暴露于ADT导致治疗抵抗,生活质量下降和由于阉割诱导代谢综合征的发展而导致的过度发病率。治疗耐药是由于前列腺癌细胞能够自适应调节雄激素受体(AR)及其变体的表达,使其达到足够的水平,从而在长期低雄激素微环境中维持AR信号传导。除了在转录中发挥作用外,AR已被证明是一种DNA许可因子,在复制中起关键作用,并且在细胞经历周期时必须降解。由于超生理睾酮的过度稳定,缺乏AR降解抑制DNA再许可,导致随后的细胞周期死亡。因此,BAT治疗的基本原理是,CRPC细胞适应性过表达AR成为一种治疗倾向,可以通过给予超生理剂量的睾酮来利用。本项目提出的BAT方法的意义在于它具有突破对ADT抗性的潜力。更重要的是,BAT还可以改善生活质量和功能能力,并最大限度地减少慢性ADT产生的代谢综合征的发病率。项目中提出的BAT战略得到临床前机制研究和试点临床研究数据的支持。该研究表明,BAT可以安全地应用于患有轻度至中度转移性负担且进展为慢性ADT的男性。在大多数接受治疗的患者中,BAT诱导PSA下降。为了进一步评估BAT作为一种新的CRPC治疗模式,本项目提出了以下具体目标:(1)开展一项II期临床试验,测试BAT对进行性CRPC男性患者的安全性和有效性。该试验将在更大的患者队列中证实前期研究的结果,并测试BAT使CRPC细胞对ADT和二线激素治疗阿比特龙和恩杂鲁胺再敏感的能力。(2)通过量化循环肿瘤细胞中AR转录本来评估BAT过程中AR的适应性自调节。本研究的目的是评估循环肿瘤细胞中AR和AR变体的水平,以支持BAT破坏AR适应性自动调节的假设。(3)开发血浆DNA生物标志物来评估对BAT的反应。该项目的目标是利用血浆循环肿瘤DNA的全外显子组测序和微滴数字PCR来鉴定个体患者癌症中的体细胞突变,从而产生一套个性化的生物标志物,可能用于预测和/或监测对BAT的反应。
英文摘要
DESCRIPTION (provided by applicant): The focus of this research project is to perform a clinical evaluation of a new treatment strategy for men with castration resistant prostate cancer (CRPC) through the administration of "Bipolar Androgen Therapy" (BAT) consisting of monthly injections of sufficient testosterone to induce a rapid rise and then fall in serum testosterone from supraphysiologic to near-castrate levels over a treatment cycle. In the current treatment paradigm for recurrent CRPC, men are treated with increasingly more potent androgen deprivation therapies (ADT). The chronic exposure to ADT leads to therapeutic resistance, reduced quality of life and excess morbidity due to development of a castration-induced metabolic syndrome. Therapeutic resistance is due to the ability of prostate cancer cells to adaptively auto-regulate the expression of the androgen receptor (AR) and its variants to sufficient levels to maintain AR signaling in a chronically low androgen microenvironment. Besides its role in transcription, AR has been demonstrated to be a DNA licensing factor that plays a critical role in replication and must be degraded as the cell goes through cycle. Lack of AR degradation due to over- stabilization by supraphysiologic testosterone inhibits DNA re-licensing resulting in death in the subsequent cell cycle. Thus, the rationale for BAT therapy is that adaptive overexpression of AR by CRPC cells becomes a therapeutic liability that can be exploited through the administration of supraphysiologic doses of testosterone. The significance of the BAT approach proposed in this Project is that is has the potential to break resistance to ADT. Of further importance, BAT may also improve quality of life and functional capacity and minimize the morbidity from the metabolic syndrome produced by chronic ADT. The BAT strategy proposed in the project is supported by preclinical mechanistic studies and data from a pilot clinical study. This study demonstrated that BAT could be safely administered to men with minimal to moderate metastatic burden that were progressing on chronic ADT. BAT induced PSA declines in the majority of treated patients. To further evaluate BAT as a new treatment paradigm for CRPC the following Specific Aims are proposed in this Project: (1) Perform a Phase II clinical trial testing the safety and efficacy of BAT in men with progressive CRPC. This trial will confirm the results from the pilot study in a larger cohort of patients and test the abiity of BAT to re- sensitize CRPC cells to ADT and second-line hormone therapies abiraterone and enzalutamide. (2) Evaluate adaptive autoregulation of AR during BAT through quantification of AR transcripts in circulating tumor cells. The goal of this Aim is to evaluate levels of AR and AR variants in circulating tumor cells to support the hypothesis that BAT disrupts adaptive auto-regulation of AR. (3) Develop plasma DNA biomarkers to evaluate response to BAT. The goal of this Aim is to use whole exome sequencing and droplet digital PCR of circulating tumor DNA in plasma to identify somatic mutations within an individual patient's cancer to produce a set of personalized biomarker that can potentially be used to predict and/or monitor response to BAT.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate Cancer
  • 批准号:
    10648749
  • 项目类别:
  • 资助金额:
    $22.97万
  • 财政年份:
    2023
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response
  • 批准号:
    10366325
  • 项目类别:
  • 资助金额:
    $52.78万
  • 财政年份:
    2021
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response
  • 批准号:
    10532225
  • 项目类别:
  • 资助金额:
    $48.86万
  • 财政年份:
    2021
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer
  • 批准号:
    9262192
  • 项目类别:
  • 资助金额:
    $26.15万
  • 财政年份:
    2014
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
海外基金